Nasus Pharma Ltd (NSRX) - Tingkat bathi reged

Simbol resmi perusahaan nasuspharma.com (NSRX)

Nasus Pharma Ltd revenues are volatile due to the market rollout phase of its nasal products. The planned gross margin on this GURU.Markets platform chart, where the value 0.00 captures the metric level, illustrates the efficiency of Taffix technology for rapid drug delivery. High FDA certification costs and patent protection create a significant barrier to entry for new players in the sector.

Nasus Pharma, Ltd. - Margin reged NSRX (periode 14.08.2025 - 20.11.2026)

Rincian analitis lan laporan data perusahaan Nasus Pharma, Ltd. (NSRX)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis dhasar perusahaan:NSRX, Nasus Pharma Ltd
Produk asil prodhuksi Nasus Pharma Ltd.

Gross margin determines the portion of revenue remaining after covering direct production costs, allowing for an assessment of cost management efficiency and the asset's capital intensity. Analyzing the gross profitability chart of Nasus Pharma Ltd (NSRX), an investor can see the impact of pharmaceutical logistics and retail distribution optimization on final profitability, where the stability of this metric confirms the resilience of drug supply chains.